The European Advanced Translational Research Infrastructure in Medicine (EATRIS) is a distributed Research Infrastructure for translational medicine. EATRIS brings together resources and services to support researchers in developing their biomedical discoveries into novel translational tools and interventions for better health outcomes. EATRIS provides access to crossdisciplinary expertise and cutting-edge technologies to successfully move early-stage research for drug development, ranging from scientific equipment, knowledge-based resources from sample collections to GMP manufacturing and regulatory guidance, closer to the patient. Research services and medicines development expertise are provided in advanced therapy medicinal products, biomarkers, imaging and tracing, small molecules and vaccines.

In the ESFRI Roadmap since 2006, EATRIS established the European Research Infrastructure Consortium (ERIC) in 2013. As of June 2021, EATRIS ERIC is supported by 14 European countries, 12 Members and 2 Observers, and regroups more that 114 academic research institutes and university medical centres across Europe. EATRIS ERIC is operating a broad range of research services and platforms – including regulatory services, training and education, and mentoring – for both academia and industry across various fields. To facilitate academic collaborations with industry, EATRIS ERIC provides research services geared towards biotech SMEs and pharmaceutical companies. EATRIS ERIC works with public funding agencies, charities and policy makers to help improve the translational research and innovation ecosystem.